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Long chain polyunsaturated fatty acids are essential nutrients for a healthy diet. The different
kinds consumed by the mother during gestation and lactation may influence pregnancy, fetal
and also neonatal outcome. The amount of fatty acids transferred frommother to fetus depends
not only on maternal metabolism but also on placental function, i.e. by the uptake, metabolism
and then transfer of fatty acids to the fetus. The third trimester of gestation is characterized by
an increase of long chain polyunsaturated fatty acids in the fetal circulation, in particular
docosahexaenoic acid, especially to support brain growth and visual development. These
mechanisms may be altered in pathological conditions, such as intrauterine growth restriction
and diabetes, when maternal and fetal plasma levels of long chain polyunsaturated fatty acids
undergo significant changes. The aim of this review is to describe the maternal and placental
factors involved in determining fetal fatty acid availability and metabolism, focusing on the
specific role of long chain polyunsaturated fatty acids in normal and pathological pregnancies.
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Fatty acids (FAs), together with glucose, lactate and
amino acids, represent essential nutrients during intra-
uterine life. Amongst fatty acids, polyunsaturated fatty
acids (PUFAs) are of particular relevance because of their
numerous physiological functions (metabolic, energetic
and structural) and for the potential influence of their
changes on some pathological conditions.
In particular, docosahexaenoic acid (DHA) is an ω-3
long chain polyunsaturated fatty acid (LC-PUFA) that has
beenwidely investigated for its critical importance on fetal
growth and especially on CNS development.
This review summarizes maternal and placental
metabolism of fatty acids with a specific focus on PUFAs,
themechanisms involved in their transfer to the fetus, their
This review was presented at The Journal of Physiology Symposium on
Altered placental function as a cause of altered fetal growth, which took
place at theAnnualMeetingofTheSociety forGynecologic Investigation
at Glasgow, UK on 20March 2009. It was commissioned by the Editorial
Board and reflects the views of the authors.
changes in pathological conditions, and their role in fetal
neurodevelopment.
Maternal fatty acids: changes with gestation
Fats are part of a balanced and wholesome diet but
the type and total amount consumed is important to
maintain the state of health. The recommended fat intake
for adults ranges between 20 and 35% of total calories
(Dietary guidelines for Americans, 2005; U.S. Department
of Health).
The most important lipids usually introduced with diet
are triglycerides and to a lesser extent phospholipids and
cholesterol esters. These are complex molecules that once
introduced into the organism cannot be wholly absorbed
by the intestine but they have to be broken into simpler
molecules by specific pancreatic enzymes.
According to the number of double bonds in the hydro-
carbon chain, fatty acids can be classified as saturated
and unsaturated, with no, or one or more double bonds,
respectively. LC-PUFAs (18 or more carbons) can be
C© 2009 The Authors. Journal compilation C© 2009 The Physiological Society DOI: 10.1113/jphysiol.2009.173062
) at unknown institution on November 2, 2009jp.physoc.orgDownloaded from J Physiol (
3442 I. Cetin and others J Physiol 587.14
further distinguished as two key families, ω-3 and ω-6
depending on the position of the first double bond in the
hydrocarbon chain. They have many distinct functions:
energetic, metabolic and structural.
Among polyunsaturated fatty acids, linoleic (LA; 18:2
ω-6) and α-linolenic (αLA; 18:3 ω-3) acids are called
‘essential fatty acids’ (EFAs) because they cannot be
synthesized endogenously but they have to be introduced
with food, in particular by consumption of vegetable oils.
EFAs are converted into their main metabolites which
are able to exert the full range of biological actions (Burdge
& Calder, 2005). Derivatives of αLA are represented
by DHA (22:6 ω-3), necessary for brain growth and
development (Innis, 2005) and eicosapentaenoic acid
(EPA; 20:5 ω-3), the precursor of series-3 prostaglandins
which inhibit platelet aggregation. LA is converted to
arachidonic acid (ARA; 20:4 ω-6), the main precursor
of prostaglandins, thromboxanes and leukotrienes,
fundamental for immune responses. DHA, EPA and
ARA may also be introduced with diet: ω-3 are mainly
present in fish, shellfish, and sea mammals and are scarce
in land animals and plants, whereas ω-6 mainly derive
from vegetable oils (Be´zard et al. 1994; Innis, 2003).
The 5–6 enzymatic chain promotes the conversion
of ARA from LA, and EPA from αLA. Due to a
competition mechanism, EPA and DHA are produced
moreefficiently thanARAinanabundanceofαLA.For this
reason, higher intakes of ω-3 are recommended for many
pathological conditions (heart diseases, atherosis and
autoimmune diseases) in order to reduce the production
of prostanoids derived from ARA, such as prostaglandin
E2 and thromboxane A2.
The mother modifies her metabolism from the
beginning of pregnancy in order to support the nutritional
needs of the feto-placental unit (Fig. 1) (Cetin et al. 2005).
The first trimester of pregnancy can be considered an
anabolic period duringwhich themother increases her net
Figure 1. Anabolic maternal metabolism
in the first trimester of pregnancy
In this phase, the mother stores lipids,
proteins and carbohydrates thanks to the
enhanced insulin sensitivity and
hyperphagia.
body weight through hyperphagia and substance storing
in adipose tissue, also under conditions of malnutrition
(Prentice & Golberg 2000; Herrera 2002). Fat storage
is facilitated by increasing the insulin responsiveness
of adipose tissue which reduces lipoprotein lipase
activity.
In the third trimester of pregnancy the fetus intensifies
its nutrient demands to support exponential tissue growth,
so maternal lipid metabolism switches to a catabolic
condition. In this stage, even short fasting periods
are associated with a condition defined as accelerated
starvation, during which the pregnant woman makes
available to the fetal–placental unit large quantities of
nutrients (Fig. 2) (Felig et al. 1970).
Adipose tissue lipolytic activity increases due to a
reduction in insulin sensitivity, under the hormonal
control of progesterone, cortisol, prolactin and leptin
(Cousins, 1991; Catov et al. 2007). High circulating
oestrogens determine a decrease in extra-hepatic
lipoprotein lipase (LPL) activity (Alvarez et al. 1996),
whereas the intestinal absorption of dietary fats increases
(Argiles & Herrera, 1989; Herrera, 2002). All these events
result in elevations of free fatty acids (FFAs) and glycerol
plasma levels taken up by the liver for the synthesis of Very
Low Density Lipoprotein (VLDL), rich in triglycerides,
quickly released into the circulation. Therefore, the
hyper-triglyceridaemia that characterizes this phase of
gestation ismainly due to an increase in VLDL production
and a decrease in its peripheral clearance (Alvarez et al.
1996; Herrera, 2002).
During the last weeks of gestation, mainly under fasting
conditions, FFAs and glycerol released from the adipose
tissue can be used for ketone bodies synthesis (Zorzano
et al. 1986; Herrera 2002). Ketone bodies and FFAs,
similarly to glucose,may easily cross the placenta to sustain
the augmented fetal metabolism. However, this is not very
relevant in quantitative terms, since fatty acids are mainly
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provided to the fetal circulation by placental transport and
eventually by elaboration of lipoproteins (Wittmaack et al.
1995; Herrera 2002).
We previously reported an increment in proportion
of total saturated fatty acids during normal pregnancy,
with a decline in ω-6 probably as a result of a decline in
the percentage of ARA, with a stable proportion of LA,
the most abundant ω-6 fatty acid in maternal plasma.
Concerning ω-3, their total amount is stable during
gestation, with an increment in percentage αLA and a
reduction in EPA and DHA (Herrera et al. 2004).
Cholesterol and triglyceride levels increase during
pregnancy, with an increment in FFAsmostly near delivery
(Herrera et al. 2004).
After delivery, LC-PUFA content in circulating
lipoproteins shows a greater decline in the triglyceride
fraction than in phospholipids or esterified cholesterol.
Plasma FFAs fall to pre-pregnancy levels within 3 days
and triglycerides in 2 weeks, although this also depends
on maternal lactation, being more rapid in women that
establish breast feeding (Montelongo et al. 1992).
Placental transfer and fetal levels of fatty acids
During intrauterine life the fetus is dependant for its
growth and development on the nutrients provided by the
mother. The amount of substrates reaching the placenta
strictly depends on maternal diet and metabolism.
However, the placenta plays a major role since its transfer
ability and metabolism together determine the amount of
nutrients in the fetal circulation (Cetin et al. 2005).
Figure 2. Catabolic maternal
metabolism in the third trimester of
pregnancy: availability of nutrients to
sustain fetal growth
eLPL: endothelial lipoprotein lipase; pLPL
placental lipoprotein lipase.
FAs are taken up by the placenta from the maternal
circulation as FFAs or as maternal lipoproteins. FAs
incorporated in maternal lipoproteins are released by
placental lipoprotein lipases. FFAs may be transferred
to the fetus by simple diffusion because the FFA
concentration gradient between the mother and the
fetus increases steadily during pregnancy (Benassayag
et al. 1999) or, more importantly, through transport
proteins located on themicrovillus or basal membranes of
trophoblast cells and on endothelial membranes of fetal
capillaries (Fig. 3).
Anumber of studies suggest that the placentamodulates
the fatty acids supply for its own metabolism and also
that of the fetus. Indeed, leptin produced by the placenta
and secreted both in the maternal and fetal circulations
stimulates lipolysis (Masuzaki et al. 1997; Hoggard et al.
2001).
Maternal lipoproteins rich in triglycerides do not
directly cross the placenta but they require hydrolysis by
placental lipoprotein lipase, so that the major source of
FAs in the fetal circulation is represented by free fatty acids
(Herrera et al. 2006). FFAs can cross the lipid bilayers by
simple diffusion or connecting to specific binding proteins
or albumin (Herrera et al. 2006).
Generally speaking, fetal fatty acids are correlated to
the maternal levels, with significantly lower total levels
in the fetal than in the maternal circulation (Cetin
et al. 2002). However, numerous studies have proved
that the FA profile is different in the fetal compared
with the maternal circulation, with higher proportions
of LC-PUFAs and a lower percentage of their precursors
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LA and αLA (Crawford et al. 1976). This phenomenon is
called ‘biomagnification’ and seems to be related to the
ability of the placenta or the fetus to increase LC-PUFA
percentages in fetal blood in order to support central
nervous system development. However, the biochemical
mechanisms responsible for this are not yet completely
clarified. In particular5 and6 desaturase activities are
very low inplacental tissue (Llanos et al. 2005). Fetal ability
todesaturate andelongate fatty acidswasdemonstrated for
LA→ARA conversion, but this capability is less efficient
for DHA (Szitanyi et al. 1999).
Biomagnification of ARA and DHA in fetal plasma
is therefore probably due to the placental ability to
preferentially transfer DHA and then ARA, ALA and LA
into fetal circulation as demonstrated by in vitro and in
vivo, and by stable isotope experiments (Ruyle et al. 1990;
Haggarty et al. 1999; Larque´ et al. 2003).
Several FA transfer proteins have been identified in the
placenta:
FABPs: different isoforms of these fatty acid binding
proteins have been recognized in the placenta. FABPpm is
locatedonly on themembrane-facingmaternal circulation
of trophoblast cells and preferentially binds LC-PUFA
(Campbell et al. 1998b) and Liver-FABP (L-FABP) located
in the cytoplasm (Campbell et al. 1998a).
FAT/CD36 (FA translocase): this is an integral
membrane protein placed in both the placental
membranes involved not only in lipid metabolism but
also in angiogenesis and inflammation (Campbell et al.
1998a).
FATPs (FA transporter proteins): integral trans-
membrane proteins located on both trophoblast
membranes (Campbell et al. 1998a).
Figure 3. Schematic view of fatty acid transport proteins in the human placenta
The location of FAT and FATP on both sides of
trophoblast cells and their lackof specificity for aparticular
type of FFA allows their transport to occur bidirectionally
from mother to fetus and vice versa. However, for its
exclusive location on the maternal side and its preference
for LC-PUFAs, FABPpm seems to be implied in their
sequestration in the placenta. (Campbell et al. 1998a;
DuttaRoy, 2000, 2008).
Once in the placenta, FAs are in part oxidized
in mitochondria to produce energy. Moreover, they
are incorporated into phospholipids while a certain
proportion of ARA is converted into prostaglandins
by cyclooxygenases. The remaining FAs are elongated,
desaturated and then released into the fetal circulation.
A different fetal blood FA profile is observed,
with proportionally higher amounts of LC-PUFAs in
comparisonwith those present in thematernal circulation.
The simultaneous evaluation of lipid and fatty acid
profile inmother and fetusduring gestation is verydifficult
under normal conditions. While it is possible to describe
this profile at different gestational ages in fetuses that are
born prematurely, this event could in itself condition or be
conditioned by an alteration in lipid profile (Olsen, 2004).
A few years ago, we described the fetal fatty acid
profile in the second half of pregnancy using fetal blood
sampling performed in utero to evaluate fetal karyotype
(Cetin et al. 2002). In that study, we reported few changes
occurring with gestation, namely an increase in saturated
(mainly palmitic acid) and polyunsaturated fatty acids,
and a decrease in oleic and consequently in the percentage
of mono-unsaturated fatty acids. No differences
were observed in the profile of LC-PUFAs during
gestation.
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Table 1. Effects of ω-3 on fetal central nervous system development
Smithers et al. 2008 Increased visual acuity (∗) VEP at 4 months: high-DHA fetuses had 1.4 cpd higher than
controls (P = 0.025)
Cheruku et al. 2002 Favoured mature neonatal sleep state ($) Infants of high-DHA mothers had a significantly lower AS/QS
ratio (P < 0.05) and < AS than infants of low-DHA mothers (P < 0.05)
Gale et al. 2008 Reduced hyperactivity (◦) Reduced risk of hyperactivity in fetuses of FO supplemented
mothers (OR = 0.34 95% CI 0.15–0.78)
Helland et al. 2003 Higher IQ at 4 years of age (§) Mean IQ 106 vs. 102 (P < 0.05)
(∗)VEP: visual evoked potential; cpd: cycle per degree
($) AS: active sleep; QS :quiet sleep
(◦) FO: fish oil, OR: odd ratio
(§) Scores on the Mental Processing Composite of the K-ABC (Kaufman Assessment Battery for Children) for children whose mothers
had taken cod liver vs. corn oil during pregnancy and lactation.
Table 2. Effects of ω-3 on pregnancy and fetal outcome
Szajewska et al. 2006 Prolong gestation Mean 1.57 days (95% CI: 0.35, 2.78)
Increase of birth weight Mean 47 or 54 g
Horvath et al. 2007 Prevent preterm birth (< 34 weeks) RR 0.39 (95% CI 0.18, 0.84)
in high risk patients
Enke et al. 2008 Influence fetal immune response DHA reduces inflammatory cytokines
Hibbeln, 2002 Deficiency increases risk of post-partum Prevalence of PPD is higher in countries with lower consumption
depression (PPD) of seafood (r = −0.81 P < 0.0001) and lower concentration of DHA
in mother’s milk (r = −0.84; P < 0.0001).
Weisinger et al. 2001 Deficiency increases blood pressure Rats fed with a deficient ω-3 diet had a higher blood pressure
than controls (P < 0.05)
RR: risk ratio
Relevance of fatty acids in fetal nutrition
The third trimester of pregnancy is characterized by
massive fetal growth and consequently a high demand of
nutrients by the fetus. During this period and through the
early weeks of life it has been estimated that the fetus needs
approximately 50mg/kg/day of ω-3 and 400mg/kg/day
of ω-6 (Clandinin et al. 1980, 1981). The brain is the
organ that most of all rapidly incorporates LC-PUFAs
for its development. In particular, DHA is selectively
incorporated into fetal brain and retina phospholipids
more than 10 times faster than LA and αLA, while ARA is
mainly used in postnatal life.
DHA confers a high degree of fluidity and flexibility
to neural and endothelial membranes of the central
nervous system. DHA is involved in neurotransmission,
regulates ion-channel activity and gene expression and
can be metabolized in neuroprotective metabolites (Innis,
2007a). Recent studies on rats suggest that deficiency
of brain ω-3 provokes a reduction of neuron size and
dendritic arborization (Ahmad et al. 2002). In rhesus
monkeys, however, a deficientω-3 diet reduces rod photo-
transduction sensitivity and delays rod recovery but does
not influence cone activity (Jeffrey & Neuringer, 2009).
In a previous study the same group noticed that in
monkeysω-3 FAdeficiency also influences fluid intake and
output without affecting serum electrolyte levels; the exact
mechanisms of these changes still have to be elucidated
(Reisbick et al. 1990).
Considering the main role of DHA for brain and
retina function and because the amount of FAs in the
fetal circulation largely depends on the FA composition
of maternal blood, many studies have investigated the
effects on brain activity with increasing maternal dietary
intake of ω-3 LC-PUFA during pregnancy and lactation.
These studies have proved that supplementation has
many favourable effects: increased visual acuity (Smithers
et al. 2008), more mature neonatal sleep state (Cheruku
et al. 2002), reduced hyperactivity (Gale et al. 2008) and
enhanced cognitive functions and attention. It is still
not known if these benefits persist to childhood and
adult life, but in a trial with 4 years follow up, children
born to supplemented mothers seem to have a higher
IQ than controls (Helland et al. 2003) (Table 1). Further
studies are required to further understand the role of
LC-PUFAs in brain development but we have to consider
that neuronal processes are complex and multifactorial
so that confounding factors such as maternal baseline
intake of LC-PUFAs, socioeconomic status or education
may influence the results.
LC-PUFAs are essential components of membrane
phospholipids not only in CNS but also in other
organs and tissues and so the potential benefits of their
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supplementation on pregnancy outcome have beenwidely
investigated in numerous studies (Table 2). In particular, a
recentmeta-analysis has shown that supplementationwith
ω-3 prolongs gestation by an average value of 1.6–2.6 days,
with a concomitant small increase in birth weight.
Moreover, it prevents preterm birth before 34 weeks of
gestation mainly in high risk pregnancies (Szajewska et al.
2006). This evidence could be explained by the influence
of high concentrations of ω-3 on the production of
prostaglandin involved in the initiation of labour.
A recent study has correlated LC-PUFA levels in the
uterus with the immune phenotype in childhood due
to their ability to influence Th1 and Th2 balance. In
particular ARA enhances the inflammatory process while
DHA decreases inflammatory cytokines; consequently
DHA supplementation seems to have a potential role in
preventing future allergies (Enke et al. 2008).
Among many effects of LC-PUFAs on fetal and
pregnancy outcomes, they seem to have an influence
also onmaternal depression. Epidemiological studies have
shown that the prevalence of post-partum depression is
higher in countries with lowω-3 intake than in those with
highest intake (Hibbeln, 2002). In particular, post-partum
depression (PPD) seems to be related to a higher ω-6/ω-3
ratio (De Vriese et al. 2003). The mechanism underlying
this observation could be the physiological reduction of
DHA contents in maternal brain lipids in the late stage
of pregnancy and during lactation. This physiological
event, associated with the evidence that pregnant women
with a current episode of major depression seem to have
lower ω-3 PUFA levels than healthy controls, seems to
predispose these patients to an elevated risk of developing
PPD (Rees et al. 2009). Few studies and with different
dosages have investigated the role ofω-3 supplementation
on PPD incidence with discordant results (Llorente et al.
2003; Freeman et al. 2006).
Besides the positive role of a suitable maternal diet
with a sufficient intake of LC-PUFAs, it is important to
underline that an unbalanced maternal diet may also have
potential dramatic consequences on the developing fetus.
In rats, abnormal maternal consumption of saturated
fatty acids may permanently alter fetal lipid and glucose
metabolism in the offspring, increasing the risk for cardio-
vascular disease in adult life (Siemelink et al. 2002; Chechi
& Cheema 2006; Chechi et al. 2009). Hypertension in
particular seems to be related to an excessive intake of
saturated FAs or to an inadequate intake of LC-PUFAs in
the perinatal period (Weisinger et al. 2001; Khan et al.
2005).
Fatty acid changes in intrauterine growth restriction
and diabetes
Fetal growth depends on a combination of different
factors: endocrine maternal state, nutritional maternal
environment and genetic potential of the fetus. The
alteration of one or more of these factors can lead to a
modification in the fetal growth trajectory. Intrauterine
growth restriction (IUGR) results frominsufficient growth
of the fetus, while gestational diabetes is associated with
increased nutrient availability and fetal overgrowth.
IUGR, which affects approximately 7–15% of
pregnancies, is a condition characterized by an inadequate
ability of the placenta to provide nutrients and oxygen to
the growing conceptus (Cetin et al. 2005; Cetin & Alvino,
2009). IUGR represents one of the principal causes of peri-
natal morbidity and mortality and is also associated with
cardiovascular disease and glucose intolerance in adult life
(De Rooij et al. 2007).
Many studies have proved that the placenta of
IUGR fetuses has a specific phenotype characterized by
altered metabolism and decreased nutrient transport. In
particular, supply of amino acids is reduced with an
increased maternal–fetal gradient of glucose (Sibley et al.
2005).
In normal pregnancy, total plasma fatty acid
concentrations are significantly higher in mothers than
in fetuses with differences in the relative amounts of some
fatty acids. Although the total amount of fatty acids is
unchanged in IUGR (Cetin et al. 2002), we have reported
changes in the LC-PUFA fetal/maternal relationship in
IUGRat the timeof fetal blood sampling,with significantly
higher F/M ratios for LA and significantly lower for DHA
and ARA. We also demonstrated that fetuses with IUGR
have a lower proportion of ARA and DHA relative to their
precursors LA andαLA in comparisonwith control infants
of similar gestational age. These data can explain the
high susceptibility of IUGR infants to brain and vascular
damage.
In a more recent study (Alvino et al. 2008) we
have evaluated the maternal and fetal blood FA profile
in pregnancies complicated by IUGR with or without
pre-eclampsia.
Pre-eclampsia is a syndrome typically correlated
with placental insufficiency beginning with a shallow
trophoblast invasion of spiral arteries similar to the
pathogenesis of IUGR (Pardi et al. 2002). However,
this condition is also characterized by an escalation in
inflammatory response to ischaemic damage that succeeds
in involving different areas of the maternal circulation.
The role of fatty acids, particularly EPA (ω-3) and ARA
(ω-6), which are precursors of prostanoids, could be very
important in limiting (ω-3 prostanoids) or enhancing
(ω-6 prostanoids) this inflammatory condition (Innis,
2005).
We reported a lower ARA/LA ratio in IUGR compared
to normal fetuses (Alvino et al. 2008). Moreover, IUGR
fetuses in pregnancies complicated with pre-eclampsia
(IUGR-PE) showed a lower percentage of ARA in
venous plasma. Their mothers had significantly higher
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concentrations of triglycerides in comparison with IUGR
only and normal mothers and this could represent a risk
factor for hypertensive disorders and development of the
metabolic syndrome in later life (Carpenter, 2007).
Both in IUGR and IUGR-PE mothers we reported
higher concentrations of FFAs associated with higher
fetal concentrations. Our group previously demonstrated
a higher expression of LPL (lipoprotein lipase) and EL
(endothelial lipase) genes in IUGR placentas that could
be associated with these results but also with the different
distribution of fatty acids in these pathological conditions
(Tabano et al. 2006; Gauster et al. 2007).
The opposite phenotype of IUGR is represented
by the fetal overgrowth that characterizes pregnancies
complicated by diabetes types I and II, and GDM
(gestational diabetes mellitus) (Catalano et al. 2007).
Intrauterine exposure to these pathologies is a significant
determinant of the development of obesity, dyslipidaemia
and early onset of type 2 diabetes mellitus in the offspring
(Schaefer-Graf et al. 2005; Harder et al. 2007). It is
known that in these conditions there is an altered
placental transport activity with an increase in glucose
and amino acid transfer (Jansson et al. 2006). Moreover,
since diabetic women have higher plasma levels of
triglycerides-lipoproteins and FFAs than healthy controls,
lipid transfer is also increased by the rising of the
maternal–fetal concentration gradient (Hollingsworth
et al. 1982; Montelongo et al. 1992). Recent evidence
showed that placenta LPL activity is increased by 39%
in Insulin Dependent Diabetes Mellitus (IDDM), but
Figure 4. Fatty acid profile in arterial and venous plasma of AGA (adequate for gestational age) and
GDM fetuses
∗P < 0.05, ∗∗P < 0.01 ANOVA and Tukey’s test between u.v. (umbilical vein) and u.a. (umbilical artery). Open
columns, u.v. AGA; shaded columns, u.a. AGA; filled columns, u.v. GDM; grey columns, u.a. GDM. SFA, saturated
fatty acids; MUFA, monounsaturated fatty acids. Data adapted from Ortega-Senovilla et al. (2009).
not in GDM patients, while the expression of L-FABP
(cytoplasmic FA binding protein) is increased both
in IDDM and GDM by 112% and 69%, respectively
(Magnusson et al. 2004). In diabetic pregnancy, a large
proportion of lipids that cross the placenta are stored
directly in the placental unit while the remainder are
released into the fetal circulation and contribute to fetal
fat deposition together with glucose (Magnusson et al.
2004).
GDM pregnancies are also associated with higher
placental/fetal weight ratios (Taricco et al. 2003) reflecting
a greater layer of exchange and/or a major density of
nutrient transporters. This leads to higher availability
of nutrients for the fetus with more tissue deposition,
particularly fat. Moreover, the quality of fatty acids that
reach the fetus could be different, because of the great
enhancement of lipolysis observed in GDM mothers
affecting the fatty acids pattern (Wijendran et al. 1999;
Thomas et al. 2004).
Innon-pregnantwomen, diabetes determines a reduced
synthesis of ARA and DHA probably due to an impaired
activity of 5 and 6 desaturases (Brenner et al. 2000).
Although this evidence has not been found in patients
with GDM (Thomas et al. 2004), both diabetic and GDM
patients show depressed levels of ARA and DHA in red
blood cell phospholipids (Wijendran et al. 1999).
We recently reported lower percentages of both ARA
and DHA in umbilical arterial plasma but not in
the umbilical vein of GDM neonates (Ortega-Senovilla
et al. 2009) (Fig. 4). These data suggest that a lower
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concentration of LC-PUFAs in neonates of GDMmothers
seems to be due to altered fetal metabolism rather
than limited placental transfer. This finding could have
potential implications for fetal and postnatal growth that
need to be investigated.
There are also important metabolic changes that
characterize pregnancies complicated by maternal obesity
but with normal glucose tolerance. Maternal obesity
is associated with a higher risk of complications like
pre-eclampsia, GDM, fetal anomalies and high birth
weight (King, 2006). In obese women, the physiological
metabolic adjustments are amplified: insulin sensitivity
is 40% lower with a consequent increase in plasma
glucose, amino acids and plasma FFAs (King, 2006).
Therefore obesity, like GDM, leads to an excess of available
nutrients for the fetus, heavily influencing its growth and
development.
Conclusions and recommendations
In conclusion, it is clear that LC-PUFA intake may
influence fetal, maternal and child health. It is therefore
advisable that pregnant and lactating women aim to
achieve an average intake of at least 200mg/day of DHA
to achieve a desirable outcome (Koletzko et al. 2007).
For this purpose, women should consume oily fish two
times a week during pregnancy, because of its beneficial
effects on vascular function and on the developing fetal
brain and retina. Only Carlson et al. (1996) reported
that supplementation of premature infants with marine
oils can adversely affect neonatal growth because of an
altered balance of ω-3 (EPA) and ω-6 (reduction of
ARA→ prostanoids→ growth factors), but usually the
supply of ARA with the diet and from maternal adipose
tissue is sufficient to maintain a correct ω-3/ω-6 ratio.
The beneficial effect of DHA on prolonging gestation and
consequently fetal weight is very consistent in different
studies (Smuts et al. 2003; Olsen et al. 2007).
Of note, since marine fish may contain large quantities
of dangerous contaminants such as polychlorinated
biphenols, dioxins and mercurial derivatives (Grandjean
& Weihe, 2003) women should be advised to consume
non-predator fish with a lower content of contaminants
(Koletzko et al. 2008).
Moreover, dietary fat intake during pregnancy and
lactation, as a proportion of total energy intake, should be
the same as that recommended for the general population.
However, further research is needed in order to better
characterize the mechanisms regulating the placental
transfer of long chain fatty acids.
Finally, maternal intake of dietary fats in the peri-
conceptional period should be investigated in future
studies in order to determine a potential role in
implantation and in early embryo development.
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